WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317955
CAS#: 88889-14-9
Description: Fosinopril Sodium is a phosphinic acid-containing ACE (angiotensin-converting enzyme) inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat.
Hodoodo Cat#: H317955
Name: Fosinopril Sodium
CAS#: 88889-14-9
Chemical Formula: C30H45NNaO7P
Exact Mass: 0.00
Molecular Weight: 585.640
Elemental Analysis: C, 61.53; H, 7.74; N, 2.39; Na, 3.93; O, 19.12; P, 5.29
Synonym: Fosinopril Sodium; Monopril; Staril; Dynacil; Fosinil; Tenso Stop; Tensocardil; Sodium, Fosinopril; SQ 28,555; SQ 28555; SQ-28,555; SQ-28555; SQ28,555; SQ28555; Squibb Brand of Fosinopril Sodium; Staril;
IUPAC/Chemical Name: sodium;(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate
InChi Key: TVTJZMHAIQQZTL-HREVRLCXSA-M
InChi Code: InChI=1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30?,39?;/m1./s1
SMILES Code: CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)[O-])C3CCCCC3.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 585.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Zhang DW, Zhang L, Liu JG, Wang CL, Shi DZ, Chen KJ. [Protective effect of
fosinopril sodium pretreatment combined with ischemic postconditioning on rat
heart underwent myocardial ischemia/reperfusion injury]. Zhonghua Xin Xue Guan
Bing Za Zhi. 2010 Jul;38(7):633-7. Chinese. PubMed PMID: 21055289.
2: Jancić B, Medenica M, Ivanović D, Janković S, Malenović A. Monitoring of
fosinopril sodium impurities by liquid chromatography-mass spectrometry including
the neural networks in method evaluation. J Chromatogr A. 2008 May
2;1189(1-2):366-73. Epub 2007 Dec 4. PubMed PMID: 18154978.
3: Janci B, Medenica M, Ivanović D, Malenović A, Marković S. Microemulsion liquid
chromatographic method for characterisation of fosinopril sodium and fosinoprilat
separation with chemometrical support. Anal Bioanal Chem. 2005 Oct;383(4):687-94.
Epub 2005 Sep 30. PubMed PMID: 16195875.
4: Mousa D, Rassoul Z, Popovich W, Hassan A, Margate V, Hawas F, Suleiman M, Al
Khader A. A new treatment forInterdialytic hyperkalemia - the use of fosinopril
sodium. Am J Nephrol. 1999;19(3):395-9. PubMed PMID: 10393377.
5: Migdalis IN, Gerolimou B, Kozanidou G, Hatzigakis SM, Karmaniolas KD. Effect
of fosinopril sodium on early carotid atherosclerosis in diabetic patients with
hypertension. J Med. 1997;28(5-6):371-80. PubMed PMID: 9604795.
6: Lewen N, Schenkenberger M, Larkin T, Conder S, Brittain HG. The determination
of palladium in fosinopril sodium (monopril) by ICP-MS. J Pharm Biomed Anal. 1995
Jun;13(7):879-83. PubMed PMID: 8562611.
7: Wang Z, Morris KR, Chu B. Aggregation behavior of fosinopril sodium--a new
angiotensin-converting enzyme inhibitor. J Pharm Sci. 1995 May;84(5):609-13.
PubMed PMID: 7658352.
8: Lozano R, Warren FV Jr, Perlman S, Joseph JM. Quantitative analysis of
fosinopril sodium by capillary zone electrophoresis and liquid chromatography. J
Pharm Biomed Anal. 1995 Feb;13(2):139-48. PubMed PMID: 7766720.
9: Friberg SE, Moaddel T, Morris KR, Abramowitz R, Amsberry KL. A lamellar liquid
crystal with fosinopril sodium. J Pharm Sci. 1994 May;83(5):677-9. PubMed PMID:
8071820.
10: Desmet W, Vrolix M, De Scheerder I, Van Lierde J, Willems JL, Piessens J.
Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention
of restenosis after coronary angioplasty. Circulation. 1994 Jan;89(1):385-92.
PubMed PMID: 8281674.
11: Brittain HG, Morris KR, Bugay DE, Thakur AB, Serajuddin AT. Solid-state NMR
and IR for the analysis of pharmaceutical solids: polymorphs of fosinopril
sodium. J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1063-9. PubMed PMID: 8123714.
12: Thakur AB, Morris K, Grosso JA, Himes K, Thottathil JK, Jerzewski RL, Wadke
DA, Carstensen JT. Mechanism and kinetics of metal ion-mediated degradation of
fosinopril sodium. Pharm Res. 1993 Jun;10(6):800-9. PubMed PMID: 8391696.
13: Duchin KL, Waclawski AP, Tu JI, Manning J, Frantz M, Willard DA.
Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an
angiotensin-converting enzyme inhibitor in healthy subjects. J Clin Pharmacol.
1991 Jan;31(1):58-64. PubMed PMID: 1646240.
14: Waldemar G, Ibsen H, Strandgaard S, Andersen AR, Rasmussen S, Paulson OB. The
effect of fosinopril sodium on cerebral blood flow in moderate essential
hypertension. Am J Hypertens. 1990 Jun;3(6 Pt 1):464-70. PubMed PMID: 2142429.
15: Morrison RA, Singhvi SM, Peterson AE, Pocetti DA, Migdalof BH. Relative
contribution of the gut, liver, and lung to the first-pass hydrolysis
(bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and
in vitro studies. Drug Metab Dispos. 1990 Mar-Apr;18(2):253-7. PubMed PMID:
1971582.
16: Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, Frantz M.
Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol. 1988
Jan;25(1):9-15. PubMed PMID: 2967089; PubMed Central PMCID: PMC1386608.
